Here is where I stand on $PEPG now
Obv very happy with the result. Considered selling in the AM but didn't because I think it's worth more. I may regret that as it continues to fade - think a lot of folks were in this for the readout.
40k pts in US so even if you only assume 10% penetration that’s $1b peak rev at $250k net price. That tracks with Novartis having bought avidity for 12 billion (a good chunk of that being the DM1 program).
Thats also conservative penetration given 1) BIC splicing correction and vHOT and 2) Novartis having just failed their pivotal and losing first mover adv.
There is probably some concern in the market about vHOT being noisy and hard to get a repeat hit on in a pivotal, after what happened to Novartis.
PEPG will read out 12.5 mpk MAD dose in 1h27 and I think they might see renal tox there. I don’t think that matters given 10mpk (what they just read out) looks BIC but there could be a negative reaction to it.
Also PEPG tends to go up by more than 100% on these readouts and then fade back down. So that could happen.
Even if you only assume 10% penetration and 33% PoS I think it’s worth $1b right now ($1B peak w/ 3x multiple x 33% pos... maybe a bit less if you discount it back to present from time of launch, but still conservative assumptions). So my default is holding but I may sell some if I’m feeling skiddish in the coming days.
I definitely won't tell you you SHOULDN'T sell if you own this, but I have not sold anything yet
$PEPG continuing to be the most predictable money tree biotech. Third time I have made >100% on this in the last 2 years lmao
I am back in $PEPG for the next readout, the odds are too rich.
I think a reasonably likely outcome is that 10mg MAD looks more or less the same safety wise as 10mg SAD. Renal biomarker (15mg SAD) appears to have more to do with acute exposure post-dose than accumulation (muscle accumulation increased ~12x from 5mg SAD to MAD but safety looked the same).
Also think it's likely 10mg MAD shows BIC splicing correction. PEPG's differentiated MOA (bind/block the repeats) appears more potent than Novartis/Dyne's (knockdown the transcript). We've yet to see saturation of the dose effect on splice index improvement, and the amount of drug in muscle is about to go way up.
I do not care about the outlier in the 5mg MAD cohort - it's unlikely (not impossible) to cause an issue in the 10mg MAD. Mgmt says it was a 97th percentile event. Literature suggests 86th percentile. Either way the odds are on your side.
I think the degree 5mg SAD splicing correction was actually encouraging.
US clinical hold is related to blood pressure drops in animals. Mgmt says they worked out the problem years ago (FDA saw this data in 2024) and this has never been seen in humans.
40K US x 10% penetration x $250K gets you to $1B in peak rev. I think DYNE and Avidity's DM1 programs account(ed) for at least a billion or two of NPV.
Could certainly crash and burn but at a little over $100M FD market cap, seems like the house is offering good odds. If it does crash let's hope RA can engineer another CLYM like transaction
3
43
4,238
Vulpes Bio retweeted
I am back in $PEPG for the next readout, the odds are too rich.
I think a reasonably likely outcome is that 10mg MAD looks more or less the same safety wise as 10mg SAD. Renal biomarker (15mg SAD) appears to have more to do with acute exposure post-dose than accumulation (muscle accumulation increased ~12x from 5mg SAD to MAD but safety looked the same).
Also think it's likely 10mg MAD shows BIC splicing correction. PEPG's differentiated MOA (bind/block the repeats) appears more potent than Novartis/Dyne's (knockdown the transcript). We've yet to see saturation of the dose effect on splice index improvement, and the amount of drug in muscle is about to go way up.
I do not care about the outlier in the 5mg MAD cohort - it's unlikely (not impossible) to cause an issue in the 10mg MAD. Mgmt says it was a 97th percentile event. Literature suggests 86th percentile. Either way the odds are on your side.
I think the degree 5mg SAD splicing correction was actually encouraging.
US clinical hold is related to blood pressure drops in animals. Mgmt says they worked out the problem years ago (FDA saw this data in 2024) and this has never been seen in humans.
40K US x 10% penetration x $250K gets you to $1B in peak rev. I think DYNE and Avidity's DM1 programs account(ed) for at least a billion or two of NPV.
Could certainly crash and burn but at a little over $100M FD market cap, seems like the house is offering good odds. If it does crash let's hope RA can engineer another CLYM like transaction
$QURE
Occam’s razor said it probably didn’t work. I usually trust Occam’s razor.
2
16
3,758
I have not seen a single fat person in America since the launch of zepbound. Market is saturated
This quoted post is unavailable.
2
6
2,640
Ayers vs. Sheep live $VKTX debate
@MartinShkreli moderating
I would pay $200 to watch
9
55
7,140
I don’t know if I’m connecting dots that don’t exist but in small cap biotech (~$200 million) a large stock move in either direction, if around when you’d expect data, usually predicts the quality of the result.
1
1,121
$PESI
Censoring your political opponents when you stand to gain from it financially is pretty cool, I see the appeal
HAB doesn't make decisions on grouting acceleration at Hanford, but at least nobody is exposed to their opposition to it any more thanks to this DOE strong-arm
4
1,739
We know that vHOT is a noisy endpoint with low correlation to splicing correction and $DYN is already moving away from it. I am wondering if $NVS, when they say “evidence of activity on secondary and exploratory endpoints” is sitting on that data so as to not hand their informational advantage, re: endpoint selection, over to $DYN and $PEPG for free.
Their massive headstart over competition is already jeopardized enough. I don’t see this as a thesis killer for splicing correction in DM1, but we’ll see.
The upside that yesterdays fail added to $PEPG is enormous, if it ends up working
If there’s one person in the entire US that deserves to contract measles it’s @SenBillCassidy
No one needs to die from measles in 2026. Misinformation and misguided policies are leaving children unprotected against a disease we know how to prevent.
The vaccine is safe and effective. Parents should talk to their doctor about protecting their children from this disease.
8
1,871
QUESTIONABLIS(™)
$QURE
15
3,628
Pretty soon we get to see round 2 of @BillCassidy vote to confirm a vaccine-denier and then whine incessantly when they continue to deny the safety/efficacy of vaccines
While I respect Dr. Overton’s experience as a physician, I have strong concerns about her nomination to be FDA Commissioner. Her lack of managerial experience does not prepare her well for leading a large organization that is already dealing with staffing and morale issues. Additionally, Dr. Overton’s active role in last week’s nonsensical vaccine executive order calls into question her commitment to standing up for sound science and protecting children’s health. That alone is almost disqualifying.
9
1,824
Can someone tell me if $MRNA’s cancer vaccine causes autism?
We don’t really need this when we have Chinese biotech slave labor speeding up the drug discovery process. Also, drug discovery is not the bottleneck for creating therapies. My $0.02
Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is designing a molecule that can bind tightly to its target. Traditionally, that's meant weeks or months of expert work per target, sifting through a large number of candidates to identify the few that work.
We wanted to test if Claude could successfully design novel protein binders from scratch (also called de novo design). With a protein design prompt written by a human expert, Claude autonomously designed protein binders against 14 out of 15 targets.
We then worked with Adaptyv Bio and Twist Bioscience, who independently built and tested the proteins Claude designed.
12
1,796
Bravo to $AMLX not only for voluntarily pulling their ALS drug from the market after it failed its confirmatory trial, but for finding/buying avexitide for a measly $35M











